Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Production Platform Using Viral Nucleocapsid
JP2025519107AActive Publication Date: 2025-06-24バクスディグム カンパニーリミティド +1
4 Cites 0 Cited by
Patent Information
- Application Number
- JP2024569232
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-23
- Filing Date
- 2023-05-23
- Publication Date
- 2025-06-24
- Estimated Expiration
- 2043-05-23
Smart Images
Figure 2025519107000001_ABST
Abstract
The expression vector for producing a target protein-fused self-assembling nanoparticle of the present invention contains a polynucleotide encoding a crystalline protein and a viral nucleocapsid as a fusion partner of the target protein. Further, the method for producing a target protein-fused self-assembling nanoparticle of the present invention includes the steps of: producing an expression vector for producing a target protein-fused self-assembling nanoparticle, which contains a target protein and a polynucleotide encoding a crystalline protein and a viral nucleocapsid as a fusion partner of the target protein; introducing the expression vector for producing a target protein-fused self-assembling nanoparticle into a host cell to produce a transformant; and culturing the transformant.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Immunogenic hbc chimera particles with enhanced stability
JP2005517380A
Molecular adjuvant
WO2019224275A1
Compositions comprising LTB and pathogenic antigens, and use thereof
WO2021171297A1
Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them
WO2022096039A1